Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2006.076497v1, 2007; 10.1373/clinchem.2006.076497
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.076497v1
53/6/1084    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cronin, M.
Right arrow Articles by Watson, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cronin, M.
Right arrow Articles by Watson, D.

Received on July 14, 2006
Accepted on March 22, 2007

Cancer Diagnostics

Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor-Positive Breast Cancer

Maureen Cronin 1*, Chithra Sangli 1, Mei-Lan Liu 1, Mylan Pho 1, Debjani Dutta 1, Anhthu Nguyen 1, Jennie Jeong 1, Jenny Wu 1, Kim Clark Langone 1, Drew Watson 1

1 Genomic Health, Inc., Redwood City, CA

* To whom correspondence should be addressed. E-mail: mcronin{at}genomichealth.com.

Background: Oncotype DXTM is a clinically validated, high-complexity, multianalyte reverse transcription-PCR genomic test that predicts the likelihood of breast cancer recurrence in early-stage, node-negative, estrogen receptor-positive breast cancer. The Recurrence ScoreTM (RS) provides a more accurate, reproducible measure of breast cancer aggressiveness and therapeutic responsiveness than standard measures. Individualized patient management requires strict performance criteria for clinical laboratory tests. We therefore investigated the analytical performance of the assay.

Methods: Assays used a pooled RNA sample from fixed paraffin-embedded tissues to evaluate the analytical performance of a 21-gene panel with respect to amplification efficiency, precision, linearity, and dynamic range, as well as limits of detection and quantification. Performance variables were estimated from assays carried out with sample dilutions. In addition, individual patient samples were used to test the optimized assay for reproducibility and sources of imprecision.

Results: Assay results defined acceptable operational performance ranges, including an estimated maximum deviation from linearity of <1 cycle threshold (CT) units over a ≥2000-fold range of RNA concentrations, with a mean quantification bias of 0.3% and CVs of 3.2%-5.7%. An analysis of study design showed that assay imprecision contributed by instrument, operator, reagent, and day-to-day baseline variation was low, with SDs of <0.5 CT.

Conclusion: The analytical and operational performance specifications defined for the Oncotype DX assay allow the reporting of quantitative RS values for individual patients with an SD within 2 RS units on a 100-unit scale.


The following articles in journals at HighWire Press have cited this article:


Home page
 JCOHome page
S. J. Mandrekar and D. J. Sargent
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
J. Clin. Oncol., August 20, 2009; 27(24): 4027 - 4034.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
K. Gwin, M. Pinto, and F. A Tavassoli
Complementary Value of the Ki-67 Proliferation Index to the Oncotype DX Recurrence Score
International Journal of Surgical Pathology, August 1, 2009; 17(4): 303 - 310.
[Abstract] [PDF]

Home page
 JCOHome page
S. S. Badve, F. L. Baehner, R. P. Gray, B. H. Childs, T. Maddala, M.-L. Liu, S. C. Rowley, S. Shak, E. D. Perez, L. J. Shulman, et al.
Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory
J. Clin. Oncol., May 20, 2008; 26(15): 2473 - 2481.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, C. Hatzis, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Oncologist, May 1, 2008; 13(5): 477 - 493.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Weber and C. Eng
Update on the Molecular Diagnosis of Endocrine Tumors: Toward -omics-Based Personalized Healthcare?
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1097 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. Marchionni, R. F. Wilson, A. C. Wolff, S. Marinopoulos, G. Parmigiani, E. B. Bass, and S. N. Goodman
Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer
Ann Intern Med, March 4, 2008; 148(5): 358 - 369.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sparano and S. Paik
Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
J. Clin. Oncol., February 10, 2008; 26(5): 721 - 728.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. K. Lau, P. C. Boutros, M. Pintilie, F. H. Blackhall, C.-Q. Zhu, D. Strumpf, M. R. Johnston, G. Darling, S. Keshavjee, T. K. Waddell, et al.
Three-Gene Prognostic Classifier for Early-Stage Non Small-Cell Lung Cancer
J. Clin. Oncol., December 10, 2007; 25(35): 5562 - 5569.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Association for Clinical Chemistry.